

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

**FIRST PATIENT ENROLLED IN THE PHASE IB/II CLINICAL TRIAL
OF MT1002 FOR ACUTE ISCHEMIC STROKE**

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the first patient has been successfully enrolled recently in the Phase Ib/II clinical trial of the Group’s independently developed drug candidate MT1002 for the treatment of acute ischemic stroke (“**AIS**”), marking that this clinical study has officially entered the substantive execution stage.

The Phase Ib/II clinical trial consists of two parts. Part 1 is a multicenter clinical study in patients with AIS to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of MT1002. Part 2 is a multicenter, randomized, standard-of-care controlled clinical study in patients with AIS to evaluate the safety and efficacy of MT1002. The first patient enrollment referred to in this announcement was achieved in Part 1 of the Phase Ib/II clinical trial.

AIS is a clinical syndrome characterized by focal cerebral ischemic and hypoxic necrosis resulting from the sudden severe stenosis or occlusion of cerebral arteries due to various causes, accompanied by corresponding neurological deficits and evidence of new cerebral infarction on computed tomography (CT) or magnetic resonance imaging (MRI). AIS is the most common type of stroke. According to the Advances in the Treatment of Acute Ischemic Stroke (2025), AIS accounted for approximately 69.6% to 72.8% of newly diagnosed stroke cases in China. According to Pharnexcloud data, the market size of acute-phase therapies for ischemic stroke in China has exceeded RMB10 billion in each of the past several years, reaching RMB12.9 billion in 2023.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi Province, the PRC, 3 July 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.